There are 2949 resources available
LBA1 - Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Presenter: Masahiro Tsuboi
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
LBA2 - Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
Presenter: Benjamin Solomon
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
Presenter: Toni Choueiri
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
Introduction and presentation of data from W4O authorship study
Presenter: Pilar Garrido Lopez
Session: Women for Oncology Forum: Women in Science
Resources:
Slides
Webcast
Women in science
Presenter: Jocalyn Clark
Session: Women for Oncology Forum: Women in Science
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Pilar Garrido Lopez
Session: Women for Oncology Forum: Women in Science
Resources:
Webcast
ESMO-MCBS: What is new and how are we expanding
Presenter: Nathan Cherny
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Slides
Webcast
How can the ESMO-MCBS contribute to a higher QoL for patients?
Presenter: Andrew Bottomley
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Slides
Webcast
Prioritising cancer systemic therapies using the ESMO-MCBS: The Israeli experience
Presenter: Raya Leibowitz-Amit
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Slides
Webcast
Shortcomings in study design: Implementation that can skew the ESMO-MCBS results
Presenter: Bishal Gyawali
Session: Challenges in the development and real-world use of the ESMO-MCBS
Resources:
Slides
Webcast